Microcide Agrees to Acquire Althexis; Joint Company Receives $60M in Financing | GenomeWeb

NEW YORK, July 30 – Microbial genomics company Microcide Pharmaceuticals said Monday it had signed an agreement to acquire Althexis in an effort to step-up its drug discovery capabilities.

Microcide of Mountain View, Calif., and Althexis of Waltham, Mass., also announced that the combined company would receive $60 million in a private round of financing. Prospect Venture Partners, New Enterprise Associates, and Schroder Ventures are particpating in the placement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.